| __timestamp | Bausch Health Companies Inc. | Novo Nordisk A/S |
|---|---|---|
| Wednesday, January 1, 2014 | 246000000 | 13762000000 |
| Thursday, January 1, 2015 | 582800000 | 13608000000 |
| Friday, January 1, 2016 | 455000000 | 14563000000 |
| Sunday, January 1, 2017 | 366000000 | 14014000000 |
| Monday, January 1, 2018 | 414000000 | 14805000000 |
| Tuesday, January 1, 2019 | 471000000 | 14220000000 |
| Wednesday, January 1, 2020 | 452000000 | 15462000000 |
| Friday, January 1, 2021 | 465000000 | 17772000000 |
| Saturday, January 1, 2022 | 529000000 | 24047000000 |
| Sunday, January 1, 2023 | 604000000 | 32443000000 |
| Monday, January 1, 2024 | 48062000000 |
Cracking the code
In the competitive world of pharmaceuticals, innovation is key to staying ahead. Novo Nordisk A/S and Bausch Health Companies Inc. are two giants in this arena, but their investment strategies in research and development (R&D) tell different stories.
From 2014 to 2023, Novo Nordisk A/S consistently outpaced Bausch Health in R&D spending. By 2023, Novo Nordisk's investment in innovation surged to over 32 billion, marking a staggering 135% increase from 2014. This commitment underscores their focus on pioneering treatments and maintaining a competitive edge.
In contrast, Bausch Health's R&D expenses grew by approximately 145% over the same period, reaching 604 million in 2023. While their growth rate is impressive, the absolute figures highlight a more conservative approach compared to Novo Nordisk.
This data reveals not just numbers, but strategic priorities that shape the future of healthcare innovation.
Comparing Innovation Spending: Novo Nordisk A/S and AbbVie Inc.
Research and Development Expenses Breakdown: Novo Nordisk A/S vs Novartis AG
Who Prioritizes Innovation? R&D Spending Compared for Novo Nordisk A/S and Takeda Pharmaceutical Company Limited
Novo Nordisk A/S or Teva Pharmaceutical Industries Limited: Who Invests More in Innovation?
Analyzing R&D Budgets: Novo Nordisk A/S vs Dr. Reddy's Laboratories Limited
Novo Nordisk A/S vs Ascendis Pharma A/S: Strategic Focus on R&D Spending
Novo Nordisk A/S vs Halozyme Therapeutics, Inc.: Strategic Focus on R&D Spending
Comparing Innovation Spending: Novo Nordisk A/S and CymaBay Therapeutics, Inc.
Comparing Innovation Spending: Novo Nordisk A/S and Travere Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Bristol-Myers Squibb Company and Bausch Health Companies Inc.
Neurocrine Biosciences, Inc. vs Bausch Health Companies Inc.: Strategic Focus on R&D Spending